Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMET Study
jRCTs051260018Recruiting
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Metformin group with Imeglimin group (2 arms). Primary endpoint: Change in serum copper at 52 weeks. Started Apr 2026; status: recruiting.
02
Drugs
metforminimeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051260018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260018.